Page 20 - New Treatment Options for Adults and Children with Overactive Bladder

Propiverine IR vs. Oxybutynin IR vs. Placebo

Design Treatment arms Duration
• Prop IR 15 mg TID
• Double-blind, N=149

randomized, placebo- • Oxy 5 mg BID 28 days
controlled N=145
• 1 wk wash-out • Placebo
N=72
Inclusion criteria: Aged ≥18 years; history of urgency or urge incontinence;
MCC ≤300 mL, body weight ≥ 45 kg

Exclusion criteria: Acute UTI; PVR>15% of MCC

Primary endpoint: Maximum cystometric capacity (Uroflow)

Prop: Propiverine; Oxy: Oxybutynin;
IR: Immediate release;
BID: bis in die (2x/d); TID: ter in die (3x/d)
PVR: postvoid residual; UTI: urinary tract infection;
MCC: Maximum cystometric capacity

Madersbacher & al. A Placebo-Controlled, Multicentre Study Comparing the Tolerability and Efficacy of Propiverine
and Oxybutynin in Patients with Urgency and Urge Incontinence. BJU International (1999), 84, 646–651